FDA approves Medtronic’s Vanta

Medtronic has secured approval from the US Food and Drug Administration (FDA) for its next-generation recharge-free implantable neurostimulator (INS) called Vanta.

The company is offering the recharge-free spinal cord stimulation platform with an extendable device life of up to 11 years.

Medtronic’s AdaptiveStim technology is used by the recharge-free device to provide personalised pain relief. Using a built-in accelerometer, it adapts to the patient’s movement or body position.

The AdaptiveStim technology has the potential to automatically adjust stimulation to maintain each patient’s optimal dose, thereby helping to exceed in-office programming.

The spinal cord stimulation platform also offers full-body MRI access with Medtronic SureScan technology.

Snapshot reporting is also be accessed by the Vanta system. Snapshot is the company’s advanced data insights solution, which provides clinicians objective reporting of patient activity levels to facilitate objective health conversations.

Clinicians and their patients, who intend to trial the Vanta neurostimulator, are also allowed to use the CareGuidePro.

CareGuidePro is a mobile application and web portal, which acts as a virtual guide for patients across their Medtronic spinal cord stimulation therapy journey.

According to the company, the Vanta is 20% smaller than its PrimeAdvanced previous generation recharge-free neurostimulator.

Medtronic neuroscience portfolio’s neuromodulation business pain therapies general manager and vice president Charlie Covert said: “We are committed to delivering innovative solutions that meets the needs of every patient.

“For those who prefer or require a recharge-free device, I believe the Vanta neurostimulator offers the best hardware and features available today. We are pleased to offer this solution, which is now part of the strongest and broadest overall portfolio in this market.” NS Medical Devices